Intradermal dissolving needle and needle device

Abstract

The present invention provides a needle that allows a drug component or a cosmetic component to penetrate into the deep layer of the epidermis, and a needle device that can easily use the required amount by suppressing inflammation or pain after application. The needle is an intradermal dissolving needle that is coated and filled with a coating agent that dissolves into the epidermis, and the needle is arranged on a wet cloth. The thickness and length of the needle are the thickness and length corresponding to the biological species to be used. In addition, the amount of the component is recorded in a manner that makes it easy to understand how many mg the component amount is in what area, and it can be divided and used by implementing a cutting line or the like. The present invention is a needle device having the above structure.

Description

[0001] This application is a divisional application of a patent application with application number 201880039955.4, filed on March 19, 2018, and with the invention name “Intradermal Dissolving Needle and Needle Device”. Technical Field

[0002] The present invention relates to an intradermal dissolving needle that allows a drug component or a cosmetic component to penetrate into a deep layer of the epidermis (skin tissue, scale tissue, bark tissue, etc.), and a needle device that can easily use a required amount of needles while suppressing inflammation or pain after application. Background Art

[0003] As shown in Patent Documents 1 and 2, conventional skin-dissolving microneedles can penetrate into the upper layer of human skin tissue (the surface layer or stratum corneum), but cannot penetrate into the deep layer of human skin tissue.

[0004] As shown in Non-Patent Document 1, a microneedle array with a size of 800 μm has the potential to allow pharmaceutical ingredients or cosmetic ingredients to penetrate into the human dermis, but causes pain to the human skin after application.

[0005] As shown in Non-Patent Document 2, the thickness of human skin is 1 to 4 mm, but as shown in Non-Patent Document 3, the thickness of cow skin is 5 to 7 mm, and that of dog skin is very thin, so the length of the needle needs to be appropriately adjusted to a length corresponding to the biological species of the object of use.

[0006] In conventional microneedle arrays, the component amounts were recorded in a manner that made it easy to understand how many mg of the component was contained in a certain area. The microneedle arrays were not easy to cut or sever by adding cut lines or implementing dotted lines, so the required component amount could not be easily attached.

[0007] Prior art literature

[0008] Patent Literature

[0009] Patent Document 1: Japanese Patent Application Publication No. 2010-82401

[0010] Patent Document 2: Japanese Patent Application Publication No. 2012-25723

[0011] Non-patent literature

[0012] Non-patent literature 1: Research and development results report, etc., "Development of a new microneedle with drug tip and its application in hair growth agent", Strategic Basic Technology Advancement Support Project for 2011 (2011 Strategic Basic Technology Development Support Project), March 2012, Precision Advanced Technology Research Institute,

[0013] http: / / www.chusho.meti.go.jp / keiei / sapoin / portal / seika / 2010 / 22h-73.pdf

[0014] Non-Patent Document 2: Structure of the Skin, April 10, 2015, Hisashi Ishihara, http: / / www.ams.eng.osaka-u.ac.jp / user / ishihara / ?p=432

[0015] Non-Patent Document 3: Know the Structure of the Body 30 (To Raise a Strong Horse) Let's Know the Structure of the Skin, Hirohiro Kaneiko

[0016] http: / / www.b-t-c.or.jp / btc_p300 / btcn / btcn68 / btcn068-04.pdf Summary of the Invention

[0017] Problems to be Solved by the Invention

[0018] The problems of the present invention are as follows.

[0019] The problem of the present invention is to enable a pharmaceutical ingredient or a cosmetic ingredient to sufficiently penetrate into the deep part of the outer skin (such as skin tissue, scale tissue, or bark tissue).

[0020] Another problem of the present invention is to suppress inflammation, pain, etc. after attaching the needle device.

[0021] In addition, the problem of the present invention is to describe the amount of the ingredient in such a way that it is easy to understand how many mg of the ingredient is in what area, and to be able to simply use the required amount of the ingredient.

[0022] The present invention is an invention completed to solve these problems.

[0023] Means for Solving the Problems

[0024] The present invention provides a dissolving type needle in the outer skin (such as skin tissue, scale tissue, or bark tissue) which is coated and filled with a pharmaceutical ingredient or a cosmetic ingredient made minute so as to penetrate into the deep part of the outer skin (such as skin tissue, scale tissue, or bark tissue). The thickness and length of the needle are the thickness and length corresponding to the biological species as the object of use.

[0025] The present invention provides a needle that dissolves in the epidermis (skin tissue, scale tissue, bark tissue, etc.), characterized in that the needle can be made of a drug component or a cosmetic component so that the drug component or the cosmetic component can be directly administered without waiting for the needle to dissolve. The thickness and length of the needle are the thickness and length corresponding to the biological species to be used.

[0026] The present invention provides a needle that dissolves in the outer skin (skin tissue, scale tissue, bark tissue, etc.), characterized in that the needle can be made of a drug component coated with a coating agent or a cosmetic component coated with a coating agent, so that the production process is simplified and the drug component or cosmetic component can be administered (without waiting for the needle to dissolve). The thickness and length of the needle are the thickness and length corresponding to the biological species to be used.

[0027] The present invention provides an intradermal (skin tissue, scale tissue or bark tissue, etc.) dissolving needle device, which is provided with needles on a wet cloth (warm wet cloth, cold wet cloth or anti-inflammatory analgesic band, etc.) to suppress inflammation and pain after application.

[0028] The present invention provides an intradermal dissolving needle device in which the component amounts are recorded and cut with cut lines or dotted lines so that the component amounts are recorded in a manner that makes it easy to understand how many mg the component amounts are in what area, and the required amount can be used simply.

[0029] For example, the amount of the drug component 10 mg (or, for example, 1.25 mg) can be written on the needle device in a manner that cuts the square centimeter corresponding to 10 mg (or, for example, 1.25 mg) of the drug component, and a cut line or a dotted line can be added to facilitate cutting, so that it can be simply cut and the required amount can be used.

[0030] The present invention provides an intradermal dissolving needle device in which the component amounts are recorded and cut so that the component amounts are recorded in a manner that makes it easy to understand how many mg of the component amount is in what area, and the required amount can be used simply.

[0031] For example, the cut is performed so that the amount of the drug component is recorded as 10 mg (or 1.25 mg, for example) per square centimeter corresponding to 10 mg (or 1.25 mg, for example), so that the required amount can be used directly.

[0032] Effects of the Invention

[0033] By making the epidermis (skin tissue, scale tissue, bark tissue, etc.) dissolving-in-type needles which are coated and filled with the micronized drug component or cosmetic component with a coating agent which dissolves in the epidermis (skin tissue, scale tissue, bark tissue, etc.), when the epidermis (skin tissue, scale tissue, bark tissue, etc.) dissolving-in-type needles are dissolved in the epidermis (skin tissue, scale tissue, bark tissue, etc.), the coated cosmetic component particles or drug component particles can penetrate into the deep layer of the epidermis (skin tissue, scale tissue, bark tissue, etc.). Therefore, the "permeability" can be improved more than the conventional needle array.

[0034] By making the needle into an intradermal dissolving type needle characterized by being made of a drug component or a cosmetic component, the drug component or the cosmetic component can be directly administered without waiting for the needle to dissolve, thereby enabling the drug component or the cosmetic component to penetrate rapidly.

[0035] By making an intradermal dissolving needle characterized by being made of a drug component coated with a coating agent or a cosmetic component coated with a coating agent, the production steps are simplified and the drug component or cosmetic component can be administered (without waiting for the needle to dissolve), thereby enabling the drug component or cosmetic component to penetrate quickly.

[0036] By making the needle device dissolving in the epidermis (skin tissue, scale tissue or bark tissue, etc.) with the above-mentioned needles arranged on a wet cloth (warm wet cloth, cold wet cloth or anti-inflammatory analgesic band), inflammation, pain, etc. can be suppressed by the wet cloth after being attached.

[0037] By making the intradermal dissolving needle device with the amount of the component recorded and cut lines or dotted lines cut into it, the required amount can be used simply. For example, the amount of the component 10 mg (or 1.25 mg, for example) is recorded on the needle device in a manner of cutting it in square centimeters corresponding to the amount of the drug component 10 mg (or 1.25 mg, for example), and the cut lines or dotted lines cut into it so that it is easy to cut, so it can be cut simply and the required amount can be used.

[0038] By making the intradermal dissolving needle device with the amount of the component recorded and cut into pieces, the required amount can be used simply. For example, the amount of the component is recorded as 10 mg (or 1.25 mg) per square centimeter corresponding to 10 mg (or 1.25 mg) of the drug component, and the required amount can be used directly. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 This is a perspective view of an intradermal dissolving needle device with the dosage of the ingredients recorded on the needle device and a cut line added.

[0040] Figure 2This is a perspective view of an intradermal dissolving needle device with the amounts of ingredients written on the needle device and the incisions indicated by dotted lines.

[0041] Figure 3 This is a perspective view of an intradermal dissolving needle device in which the amount of the component is recorded and the cutting is performed.

[0042] Figure 4 This is a cross-sectional view of a needle device in which nanoparticles or cosmetic ingredients that are smaller than nanoparticles or pharmaceutical ingredients that are similarly smaller are coated with a coating agent that dissolves into the outer skin and then embedded.

[0043] Figure 5 A cross-sectional view of a needle device having a multilayer structure in which nanoparticles or cosmetic ingredients smaller than nanoparticles or similarly miniaturized drug ingredients are coated with a coating agent that dissolves into the outer skin, the miniaturized cosmetic ingredients or drug ingredients are formed into a layer on the coated coating agent as needed, and a layer coated with a coating agent is further formed thereon.

[0044] Figure 6 The invention is a cross-sectional view of a needle device having a multilayer structure in which nanoparticles or cosmetic ingredients smaller than nanoparticles or similarly miniaturized drug ingredients are coated with a coating agent that dissolves into the outer skin, the miniaturized cosmetic ingredients or drug ingredients are formed into a layer on the coated coating agent, and a coating layer is further formed on the layer with a coating agent. DETAILED DESCRIPTION

[0045] Nanoparticles or cosmetic ingredients 2 that are smaller than nanoparticles or similarly smaller pharmaceutical ingredients 2 are coated with a coating agent 3 that dissolves into the epidermis (skin tissue, scale tissue, or bark tissue, etc.), and then a dissolving needle 4 is embedded in the epidermis (skin tissue, scale tissue, or bark tissue, etc.). Figure 5 , Figure 6 In this way, a multilayer structure is formed by forming a layer of the microcosmetic component 2 or the similarly micromedical component 2 on the applied coating agent 3, and further forming a layer coated with the coating agent 3 on the layer. Figure 5 and Figure 6 The needle 4 has a four-layer structure, but may have a multi-layer structure with more than four layers. The thickness and length of the needle 4 are those corresponding to the biological species to be used.

[0046] The intradermal dissolving needle 4 itself can be made of a cosmetic component 2, a drug component 2, a coated cosmetic component 2, or a coated drug component 2. The coated drug component 2 or the cosmetic component 2 built into the needle 4 may be different from the cosmetic component 2, the drug component 2, the coated cosmetic component 2, or the coated drug component 2 used to make the needle 4 itself. For example, a drug component for hypertension is coated and built into the needle 4, and the needle 4 itself can be made of an antibacterial drug. The thickness and length of the needle 4 are the thickness and length corresponding to the biological species to be used.

[0047] Any one or more of the needles 4 mentioned above are arranged on a wet cloth (warm wet cloth, cold wet cloth, anti-inflammatory analgesic band, etc.) 1. However, in the case where a wet cloth containing an anti-inflammatory agent cannot be used due to reasons such as allergy to the anti-inflammatory agent or the analgesic, or when it is used for a biological species that is ineffective against the anti-inflammatory agent or the analgesic, the needles 4 are arranged in the patch 1 for use.

[0048] The composition of the coating agent 3 includes: fatty acid esters such as nucleic acid esters, nucleic acid salts, cholesterol, sucrose fatty acid esters, glycerol fatty acid esters, fatty acids including keratin, fatty acid salts, phosphates, phosphates including phospholipids, polylactates, polylactic acid esters (including copolymers of polylactic acid and polyglycolic acid), sugars (including mucopolysaccharides containing hyaluronic acid, dextran, maltose, glucose, sucrose, galactose, lactose, cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, trehalose, peptidoglycan, polyglycolic acid, chitin, etc.), amino acid esters, amino acid salts, proteins (including gelatin, collagen, keratin, etc.), peptides, lignin, biodegradable polymers such as polyvinyl alcohol and polyvinyl pyrrolidone, fullerenes, vitamins, hormones, antigens, antibodies, matrices, enzymes, at least any one of which is a biocompatible substance; derivatives of the aforementioned substances; or mixtures thereof.

[0049] The above is an example, and any biocompatible substance may be used as long as the cosmetic component or drug component is applied and dissolved in the epidermis (skin tissue, scale tissue, bark tissue, etc.).

[0050] The composition of the above-mentioned intraskin-dissolving needle 4 includes: nucleic acid esters, nucleic acid salts, cholesterol, sucrose fatty acid esters, fatty acid esters containing glycerol fatty acid esters, fatty acids containing keratin, fatty acid salts, phosphates, phosphates containing phospholipids, polylactates, polylactic acid esters (including copolymers of polylactic acid and polyglycolic acid), sugars (including mucopolysaccharides containing hyaluronic acid, dextran, maltose, glucose, sucrose, galactose, lactose, cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, trehalose, peptidoglycan, polyglycolic acid, chitin, etc.), amino acid esters, amino acid salts, proteins (including gelatin, collagen, keratin, etc.), peptides, lignin, polyvinyl alcohol, polyvinyl pyrrolidone and other biodegradable polymers, fullerenes, vitamins, hormones, antigens, antibodies, matrices, enzymes, at least any one of which is a biocompatible substance; derivatives of the aforementioned substances; or mixtures thereof.

[0051] The above is an example, and any biocompatible material may be used as long as it can be formed into needles and dissolved in the outer skin (skin tissue, scale tissue, bark tissue, etc.).

[0052] In addition, the amount of the component is recorded in the intradermal dissolving needle device 1 in a manner that makes it easy to understand how many mg of the component is in what area, and cut lines are added or dotted lines are cut to facilitate cutting, or to allow cutting and attaching of an appropriate amount. Cut lines can be applied to the surface where the needle 4 is arranged, the surface opposite to the surface where the needle 4 is arranged, or both surfaces.

[0053] For example, the intradermal dissolving needle device 1 may be cut with a square centimeter corresponding to 10 mg (or 1.25 mg) of the drug component and a cut line or a dotted line may be added to indicate the amount of the drug component, 10 mg (or 1.25 mg).

[0054] Example

[0055] Although the embodiments are shown in the drawings, the present invention is not limited to Figure 1 to Figure 6 For example, the needle device 1 is shown in the figure as a rectangular parallelepiped, but may be in other three-dimensional shapes.

[0056] Figure 1 : This is a three-dimensional view of a needle device 1 in which the amount of ingredients is recorded in the epidermis (skin tissue, scale tissue, bark tissue, etc.) in a dissolving type needle device 1 in a manner that makes it easy to understand how many mg of ingredients are in a certain area, and a cutting line is added. The cutting line can be applied to the surface where the needle 4 is arranged, the surface opposite to the surface where the needle 4 is arranged, or both surfaces.

[0057] As a representative example, a diagram is shown in which the component amount is set to 10 mg and the cut line is applied to the surface opposite to the surface on which the needle 4 is arranged.

[0058] Figure 2: This is a perspective view of a needle device 1 in which the amount of a component is recorded in the epidermis (skin tissue, scale tissue, bark tissue, etc.) and cut with a dotted line so that it is easy to understand how many mg the component is in a certain area. As a representative example, the figure shows a component amount of 10 mg.

[0059] Figure 3 : This is a perspective view of a needle device 1 that dissolves in the outer skin (skin tissue, scale tissue, bark tissue, etc.) and cuts the needle device 1 by recording the amount of the component in a manner that makes it easy to understand how many mg the component is in a certain area. As a representative example, the diagram shows a component amount of 10 mg.

[0060] Figure 4 : It is a cross-sectional view of a needle device 1 that coats nanoparticles or cosmetic ingredients 2 that are smaller than nanoparticles or similarly smaller pharmaceutical ingredients 2 with a coating agent 3 that dissolves into the epidermis (skin tissue, scaly tissue, or bark tissue, etc.), and then embeds a dissolving needle 4 into the epidermis (skin tissue, scaly tissue, or bark tissue, etc.).

[0061] Figure 5 : A cross-sectional view of a needle device 1 having a soluble needle 4 built into the epidermis (skin tissue, scale tissue, bark tissue, etc.) by coating a coating agent 3 that dissolves in the epidermis (skin tissue, scale tissue, bark tissue, etc.) with a nanoparticle or a cosmetic ingredient 2 that is smaller than a nanoparticle or a similarly smaller drug ingredient 2, forming a layer on the coated coating agent 3 as needed, and further forming a layer coated thereon with the coating agent 3, and a multilayer structure. As a representative example, a 4-layer structure is shown in the figure, but there are also multilayer structures with more than 4 layers.

[0062] Figure 6 : A cross-sectional view of a needle device 1 having a soluble needle 4 built into the epidermis (skin tissue, scale tissue, bark tissue, etc.) by coating a coating agent 3 that dissolves in the epidermis (skin tissue, scale tissue, bark tissue, etc.) with a nanoparticle or a cosmetic ingredient 2 that is smaller than a nanoparticle or a similarly smaller drug ingredient 2, forming a layer on the coated coating agent 3, and further forming a layer coated with the coating agent 3, as well as a multilayer structure. As a representative example, a four-layer structure is shown in the figure, but a multilayer structure with more than four layers is also possible.

[0063] Industrial Applicability

[0064] The present invention is not only a needle device for humans but also a needle device for animals or plants, and therefore can also be used in industries in the veterinary field or the agricultural field.

[0065] Explanation of symbols

[0066] 1: Wet cloth or patch

[0067] 2: Miniaturized cosmetic ingredients or miniaturized pharmaceutical ingredients

[0068] 3: Coating agent

[0069] 4: Needle

Claims

1. An intradermal dissolving needle device, It is characterized in that The present invention is an intradermal dissolving needle device for administering a pharmaceutical component or a cosmetic component, and the intradermal dissolving needle device comprises: Particles having a structure in which a micronized drug component or micronized cosmetic component is coated with a coating agent that dissolves in the outer skin, the micronized drug component or micronized cosmetic component is formed into a layer on the coated coating agent, and a layer coated with the coating agent is further formed thereon, an intradermal dissolving needle having a thickness and a length corresponding to the biological species to be used, and containing the particles; and A wet cloth or patch equipped with the intradermal dissolving needle, The wet cloth or patch is free of the particles.

2. An intradermal dissolving needle, It is characterized in that The intradermal dissolving needle is used to administer pharmaceutical ingredients or cosmetic ingredients, and contains the particles of claim 1 and particles coated with a coating agent that dissolves into the outer skin for the miniaturized pharmaceutical ingredients or miniaturized cosmetic ingredients, and has a thickness and length corresponding to the biological species to be used.

3. An intradermal dissolving needle, It is characterized in that It contains the particles of claim 1 or the particles of claim 2, and the intradermal dissolving needle is composed of a pharmaceutical component or a cosmetic component or a pharmaceutical component coated with a coating agent or a cosmetic component coated with a coating agent, and has a thickness and length corresponding to the biological species to be used.

4. A needle device, It is characterized in that The needle device uses the needle according to any one of claim 1, claim 2, or claim 3, can be used in a split manner, and has the product name and component amount indicated on the surface.

5. The needle device according to claim 1 or 4, in, The coating agent contains a phosphoric acid ester.

6. The intradermal dissolving needle according to claim 2 or 3, in, The coating agent contains a phosphoric acid ester.

7. The needle device according to claim 1 or 4, in, The coating agent comprises a phospholipid.

8. The needle device according to claim 5, in, The coating agent comprises a phospholipid.

9. The intradermal dissolving needle according to claim 2 or 3, in, The coating agent comprises a phospholipid.

10. The intradermal dissolving needle according to claim 6, in, The coating agent comprises a phospholipid.

Images